RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different
ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and
help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as
lomustine, work in different ways to stop the growth of tumor cells, either by killing the
cells or by stopping them from dividing. It is not yet known which regimen of bevacizumab
given together with lomustine is most effective in treating patients with glioblastoma
multiforme in first recurrence.
PURPOSE: The primary objective of this study is to investigate whether the addition of
bevacizumab to lomustine improves overall survival (OS) in patients with recurrent
glioblastoma compared to treatment with lomustine alone.
Phase:
Phase 3
Details
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC